SecBot SecBot
PRESS-RELEASE ·Filed May 15, 2026

ANVS

Annovis Bio Inc.
BEARISH
Impact 6/10
Horizonmonths Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▼ Bearish

The EPS miss and accelerating cash burn are negative signals for a pre-revenue biotech with no near-term catalyst until summer 2026 enrollment completion. Monitor cash runway closely, the $14.2M cash (plus $10M offering) likely funds operations only into late 2026, requiring additional financing before Phase 3 data readout in early 2027. The 85% enrollment milestone is positive but insufficient to offset the financial deterioration.

DirectionBearish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$2.06
T+0 close · May 15, 2026 · via day close
Latest settled
−8.25%
T+60 · $1.89
Vs SPY
−12.77%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 15 $2.06entry
  2. T+1 · 6mo ago −0.49%α −0.42% · $2.05
  3. T+5 · 6mo ago +8.25%α +7.29% · $2.23
  4. T+20 · 5mo ago −13.59%α −15.71% · $1.78
  5. T+60 · 3mo ago −8.25%α −12.77% · $1.89

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Annovis Bio reported Q1 2026 EPS of -$0.63, significantly below the -$0.35 consensus estimate, with R&D expenses tripling to $16.7M as the Phase 3 AD trial enrollment reached 85%. Cash burn accelerated to $17.6M net loss for the quarter, leaving $14.2M cash on hand (plus $10M from an April offering), funding operations into late 2026 but raising dilution risk ahead of pivotal data readouts in early 2027.

Key Financial Metrics

EPS
−$0.63
est −$0.35 · -80.0%
Rating
miss

Key Facts

  • Q1 2026 EPS -$0.63 vs consensus -$0.35 (80% miss); net loss widened to $17.6M from $5.5M YoY
  • Cash and equivalents $14.2M at March 31, 2026, down from $19.5M at year-end 2025; excludes $10M April offering
  • Phase 3 AD trial 85% enrolled; full enrollment expected summer 2026, top-line symptomatic data early 2027
  • R&D expenses $16.7M vs $5.0M YoY, driven by Phase 3 trial costs; G&A flat at $1.3M
  • Shares outstanding 28.5M at March 31, up from 27.2M at year-end 2025, reflecting ongoing dilution

Financial Impact

EPS miss of -$0.28 vs consensus; net loss increased $12.1M YoY; cash burn rate ~$5.9M/month

epscashnet lossdilution

Risk Factors

  • Cash runway insufficient to reach Phase 3 data readout without dilutive financing
  • EPS miss and widening losses may pressure the stock given limited analyst coverage (1 analyst)
  • Regulatory and clinical execution risk for buntanetap NDA submission in early 2027

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3295755

US Market Status

Market Closed · Opens in 5h 49m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 15, 2026